Quantum Genomics (Quantum Genomics) EPS (Basic) : $-0.82 (TTM As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Quantum Genomics EPS (Basic)?

Quantum Genomics's basic earnings per share (Basic EPS) for the six months ended in Dec. 2022 was $-0.40. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.82.

Quantum Genomics's EPS (Diluted) for the six months ended in Dec. 2022 was $-0.40. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.82.

Quantum Genomics's EPS without NRI for the six months ended in Dec. 2022 was $-0.40. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2022 was -0.82.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Quantum Genomics EPS (Basic) Historical Data

The historical data trend for Quantum Genomics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantum Genomics EPS (Basic) Chart

Quantum Genomics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EPS (Basic)

Get a 7-Day Free Trial

-0.87

-0.56

-0.53

-0.68

-0.76

Quantum Genomics Semi-Annual Data
	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22
EPS (Basic)	Get a 7-Day Free Trial															-0.29	-0.24	-0.42	-0.42	-0.40

Quantum Genomics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Quantum Genomics's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-26.414	-	0)	/	34.764
	=	-0.76

Quantum Genomics's Basic EPS for the quarter that ended in Dec. 2022 is calculated as

Basic EPS (Q: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-13.751	-	0)	/	34.764
	=	-0.40

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.82

Quantum Genomics (OTCPK:QNNTF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Quantum Genomics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Quantum Genomics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Quantum Genomics (Quantum Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quantum Genomics (OTCPK:QNNTF) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

ALQGC:France 2QG:Germany

Address

33, Rue Marbeuf, Paris, FRA, 75008

Website

https://quantum-genomics.com

Quantum Genomics is a biopharmaceutical company engaged in developing new products for unmet needs in the field of cardiovascular diseases, high blood pressure, and heart failure. The company products include firibastat, QGC006, QGC011, and others.